drugset / Trial / NCT06227065
Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids
Phase 2
Not yet recruiting
28 enrolled
Hospital Centre Biel/Bienne
Fond'action contre le cancer · collabLindenhofgruppe AG · collabSpitalzentrum Biel · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Based on the unmet clinical need to reduce invasiveness of treatment of low grade NMIBC, the investigators conduct this prospective, open label, single arm and single center phase II trial. The investigators aim to use drug screens in PDOs to guide neoadjuvant intravesical instillation therapy with either Epirubicin, Mitomycin C, Gemcitabine or Docetaxel to achieve chemoresection NMIBC.
Timeline
- Start
- 2026-12-01
- Primary completion
- 2030-11-30
- Completion
- 2031-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 37.5 mg | Other |
| Subject | Epirubicin | Small molecule | 50 mg | Other |
| Subject | Gemcitabine | Small molecule | 1000 mg | Other |
| Subject | Mitomycin | Unknown | 20 mg | Other |